TY - JOUR
T1 - Recategorization of psoriasis severity
T2 - Delphi consensus from the International Psoriasis Council
AU - International Psoriasis Council Board Members and Councilors
AU - Strober, Bruce
AU - Ryan, Caitriona
AU - van de Kerkhof, Peter
AU - van der Walt, Joelle
AU - Kimball, Alexa B.
AU - Barker, Jonathan
AU - Blauvelt, Andrew
AU - Bourcier, Marc
AU - Carvalho, Andre
AU - Cohen, Arnon
AU - Foley, Peter
AU - Evans, Colby
AU - Gisondi, Paolo
AU - Griffiths, Chris
AU - Hamdy El-Sayed, Mahira
AU - Eschevarria, Cristina
AU - Finlay, Andrew
AU - Kalb, Robert
AU - Leonardi, Craig
AU - Lynde, Chuck
AU - Murphy, Ruth
AU - Murakami, Masamoto
AU - Okubo, Yukari
AU - Prens, Errol
AU - Puig, Lluís
AU - Seyger, Marieke
AU - Skov, Lone
AU - Terui, Tadashi
AU - Valenzuela, Fernando
AU - Ward, Nicole
AU - Wu, Jashin
AU - Zheng, Min
N1 - Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis. Objective: To develop a consensus statement on the classification of psoriasis severity. Methods: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity. Results: After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy. Limitations: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients. Conclusion: The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
AB - Background: Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis. Objective: To develop a consensus statement on the classification of psoriasis severity. Methods: A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity. Results: After completion of the exercise, 7 severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy. Limitations: This effort might have suffered from a lack of representation by all relevant stakeholders, including patients. Conclusion: The consensus statement describes 2 categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
KW - BSA
KW - psoriasis
KW - severity
KW - systemics
KW - topicals
UR - http://www.scopus.com/inward/record.url?scp=85074848177&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.08.026
DO - 10.1016/j.jaad.2019.08.026
M3 - Article
C2 - 31425723
AN - SCOPUS:85074848177
SN - 0190-9622
VL - 82
SP - 117
EP - 122
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -